Granted Patent
B2
US 12,447,195 · App. 18/498,843 · Granted Oct 21, 2025
Engineered SIRPα variants and methods of use thereof
Inventors:
Jiin-Tarng Wang (Taichung, TW); Han-Fang Teng (New Taipei, TW); Pan-Hsien Kuo (Taoyuan, TW); Chi-Ling Tseng (Taipei, TW); Zong Sean Juo (New Taipei, TW)
Assignee:
FBD Biologics Limited
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This disclosure relates to engineered SIRPα variants, and methods of use thereof.
Claims (4)
1. An engineered SIRPα polypeptide comprising SEQ ID NO: 9.
2. The engineered SIRPα polypeptide of claim 1 , wherein the engineered SIRPα polypeptide further comprises a CH2 domain, a CH3 domain, and optionally a hinge region.
3. The engineered SIRPα polypeptide of claim 1 , wherein the engineered SIRPα polypeptide comprises SEQ ID NO: 23.
4. A method of treating a human subject having cancer that comprises cancer cells that express CD47, the method comprising administering a therapeutically effective amount of a composition comprising the engineered SIRPα polypeptide of claim 3 , to the human subject.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 21, 2024
From: WANG, JIIN-TARNG; TENG, HAN-FANG; KUO, PAN-HSIEN; TSENG, CHI-LING; JUO, ZONG SEAN
To: FBD BIOLOGICS LIMITED
Reel/Frame 067799/0863 →
Continuity (3)
Continuation
PCTUS2022052373
· Dec 9, 2022
Provisional Application
63292267
· Dec 21, 2021
References Cited (46)
US 9944911B2
· Ring et al.
· 2018
[cited by applicant]
US 9969789B2
· Uger et al.
· 2018
[cited by applicant]
US 20060275844A1
· Linke
· 2006
[cited by examiner]
US 20080280297A1
· Dalla-Favera
· 2008
[cited by examiner]
US 20110190157A1
· Kipps
· 2011
[cited by examiner]
US 20120178111A1
· Diamandis
· 2012
[cited by examiner]
AU 2013362789B2
· 2018
[cited by applicant]
AU 2016210755B2
· 2021
[cited by applicant]
CN 104136037B
· 2018
[cited by applicant]
CN 108350048A
· 2018
[cited by applicant]
CN 106146670B
· 2019
[cited by applicant]
CN 105073780B
· 2019
[cited by applicant]
EP 3287470A1
· 2018
[cited by applicant]
EP 3331902
· 2018
[cited by applicant]
EP 2931752B1
· 2019
[cited by applicant]
EP 2804617B1
· 2020
[cited by applicant]
EP 3128005B1
· 2021
[cited by applicant]
EP 3575326B1
· 2022
[cited by applicant]
WO WO2008077546
· 2008
[cited by applicant]
WO WO2013109752
· 2013
[cited by applicant]
WO WO2014094122
· 2014
[cited by applicant]
WO WO2016023040
· 2016
[cited by applicant]
WO WO2016169261A1
· 2016
[cited by applicant]
WO WO2017027422
· 2017
[cited by applicant]
WO WO2019084692A1
· 2019
[cited by applicant]
WO WO2022063316
· 2022
[cited by applicant]
Baxevanis (Expert Opinion: Drug Discovery, vol. 3, No. 4, p. 441-452, 2008) (Year: 2008).
[cited by examiner]
Huang (Computation and Structural Biotechnology Journal, vol. 19, p. 5494-5503, 2021) (Year: 2021).
[cited by examiner]
Dhanda et al., “Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity,” Immunology, Jan. 2018, 153(1):118-32.
[cited by applicant]
GenBank Acession No. NP_542970.1, “tyrosine-protein phosphatase non-receptor type substrate 1 isoform 1 precursor [
[cited by applicant]
Jiang et al., “Targeting CD47 for cancer immunotherapy,” Journal of Hematology & Oncology, Dec. 2021, 14(1), 18 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2022/052373, mailed on Jun. 15, 2023, 15 pages.
[cited by applicant]
Seiffert et al., “Signal-regulatory protein α (SIRPα) but not SIRPβ is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34+ CD38-hematopoietic cells,” Blood, The Journal of…
[cited by applicant]
Sikic et al., “First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers,” Journal of Clinical Oncology, Apr. 2019, 37(12):946, 11 pages.
[cited by applicant]
UniProt ID No. P78324, “Tyrosine-protein phosphatase non-receptor type substrate 1,” Mar. 28, 2003, 13 pages.
[cited by applicant]
Wang et al., “HCB101: A safe and effective ligand trap therapeutic targeting the CD47-SIRPa signaling pathway for cancer treatment,” Abstract, Journal of Immunotherapy, Nov. 2022, 10(2):A1-595, 1 page.
[cited by applicant]
Weiskopf et al., “Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies,” Science. Jul. 2013, 341(6141):88, 13 pages.
[cited by applicant]
Yanagita et al. “Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy,” JCI Insight, Jan. 2017, 2(1), 16 pages.
[cited by applicant]
EP Partial Supplementary European Search Report in European Appln. No. 22912284.1, mailed on Mar. 31, 2025, 21 pages.
[cited by applicant]